Description
Otezla (generic name: apremilast) is an oral prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat certain inflammatory conditions. It is commonly prescribed for:
-
Plaque psoriasis in adults with moderate to severe symptoms.
-
Psoriatic arthritis in adults.
-
Oral ulcers associated with Behçet’s disease.
Otezla belongs to a class of drugs known as phosphodiesterase 4 (PDE4) inhibitors, which work by reducing inflammation in the body.
How Otezla Works
Unlike biologics that are injected, Otezla is an oral small-molecule therapy. It works by blocking the PDE4 enzyme, which plays a role in producing inflammatory mediators in the immune system. By lowering the activity of PDE4, Otezla helps reduce swelling, redness, pain, and skin cell overgrowth associated with psoriasis and psoriatic arthritis.
Benefits of Otezla (Apremilast)
Patients prescribed Otezla may experience:
-
Improved skin clearance in plaque psoriasis.
-
Reduced joint pain, stiffness, and swelling in psoriatic arthritis.
-
Relief from painful mouth ulcers in Behçet’s disease.
-
Convenience of oral dosing (no injections required).
-
Non-immunosuppressive therapy, lowering infection risk compared to biologics.
Otezla Dosage and Administration
-
Initial dose: Otezla is started with a titration schedule over 5 days to minimize stomach upset.
-
Maintenance dose: 30 mg taken orally, twice daily (morning and evening).
-
Can be taken with or without food.
-
Tablets should be swallowed whole and not crushed or split.
Reviews
There are no reviews yet.